The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
نویسندگان
چکیده
Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK Consensus Statements for patient selection, treatment schedules, monitoring protocols and patient assessment criteria for ECP. The recent literature has been reviewed and considered when writing this update. Most notably, the national transition from the UVAR XTS® machine to the new CELLEX machine for ECP with dual access and a shorter treatment time has led to relevant changes in these schedules. This consensus statement updates the previous statement from 2007 on the treatment of CTCL and GvHD with ECP using evidence based medicine and best medical practise and includes guidelines for both children and adults.
منابع مشابه
Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft- versus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma
The standard of care for treatment of organ transplant rejection is immunosuppression, with the particular regimen dictated by the organ being transplanted. As organ transplantation success rates have improved, more patients are facing the morbidity and mortality associated with immunosuppressive therapies developed to prevent rejection of the transplanted organ. Immunosuppressive therapies are...
متن کاملExtracorporeal photopheresis: how, when, and why.
Extracorporeal photopheresis (ECP) is a well-tolerated procedure that suppresses T-lymphocyte activity in a clonally-specific way. It is an effective therapy that has established indications in the management of cutaneous T-cell lymphoma, graft-versus-host disease and some scenarios of solid-organ transplant rejection. It is being used increasingly around the world. Its applications are evolvin...
متن کاملGuidelines on the use of extracorporeal photopheresis
BACKGROUND After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Among the major studied condit...
متن کاملExtracorporeal Photopheresis as a Treatment of Graft-versus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma
متن کامل
Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft-versus-Host Disease, Autoimmune Disease, and Cutaneous T-Cell Lymphoma
The following Protocol contains medical necessity criteria that apply for this service. It is applicable to Medicare Advantage products unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Preauthorization is required.* Please note that payment for covered services is subject to eligibility and the...
متن کامل